Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Calidi Biotherapeutics (NYSE:CLDI) will be featured on Bloomberg TV's RedChip Small Stocks, Big Money™ show on March 1, 2025, at 7 p.m. ET. During the interview, CFO Andrew Jackson discusses the company's oncolytic virotherapy (OV) platforms for cancer treatment.
The company's technology utilizes stem cells to protect, amplify, and enhance oncolytic viruses for targeting cancer cells. Their pipeline includes CLD-101, currently in Phase 1/1b trials with upcoming Phase 1b/2 study, and CLD-201 targeting Phase 1 initiation in 2025. The company estimates its addressable U.S. market at $13-15 billion.
Calidi Biotherapeutics (NYSE:CLDI) sarà presentata nel programma RedChip Small Stocks, Big Money™ di Bloomberg TV il 1 marzo 2025, alle 19:00 ET. Durante l'intervista, il CFO Andrew Jackson discute delle piattaforme di viroterapia oncolitica (OV) dell'azienda per il trattamento del cancro.
La tecnologia dell'azienda utilizza cellule staminali per proteggere, amplificare e migliorare i virus oncolitici per colpire le cellule tumorali. Il loro pipeline include CLD-101, attualmente in fase di sperimentazione 1/1b con uno studio di fase 1b/2 in arrivo, e CLD-201 che mira all'inizio della fase 1 nel 2025. L'azienda stima il suo mercato potenziale negli Stati Uniti tra i 13 e i 15 miliardi di dollari.
Calidi Biotherapeutics (NYSE:CLDI) aparecerá en el programa RedChip Small Stocks, Big Money™ de Bloomberg TV el 1 de marzo de 2025, a las 7 p.m. ET. Durante la entrevista, el CFO Andrew Jackson habla sobre las plataformas de viroterapia oncolítica (OV) de la empresa para el tratamiento del cáncer.
La tecnología de la empresa utiliza células madre para proteger, amplificar y mejorar los virus oncolíticos dirigidos a las células cancerosas. Su pipeline incluye CLD-101, actualmente en ensayos de Fase 1/1b con un próximo estudio de Fase 1b/2, y CLD-201 que apunta a iniciar la Fase 1 en 2025. La empresa estima su mercado direccionable en EE. UU. entre 13 y 15 mil millones de dólares.
Calidi Biotherapeutics (NYSE:CLDI)는 2025년 3월 1일 오후 7시 ET에 Bloomberg TV의 RedChip Small Stocks, Big Money™ 프로그램에 출연할 예정입니다. 인터뷰 중 CFO Andrew Jackson은 암 치료를 위한 온콜리틱 바이러스 치료(OV) 플랫폼에 대해 논의합니다.
회사의 기술은 줄기 세포를 활용하여 온콜리틱 바이러스를 보호하고, 증대시키며, 암세포를 표적화하는 데 도움을 줍니다. 그들의 파이프라인에는 현재 1/1b 단계의 임상 시험 중인 CLD-101과 2025년에 1단계 시작을 목표로 하는 CLD-201이 포함되어 있습니다. 회사는 미국의 잠재적 시장 규모를 130억에서 150억 달러로 추정하고 있습니다.
Calidi Biotherapeutics (NYSE:CLDI) sera présenté dans l'émission RedChip Small Stocks, Big Money™ de Bloomberg TV le 1er mars 2025 à 19h00 ET. Lors de l'interview, le CFO Andrew Jackson discute des plateformes de virothérapie oncolytique (OV) de l'entreprise pour le traitement du cancer.
La technologie de l'entreprise utilise des cellules souches pour protéger, amplifier et améliorer les virus oncolytiques ciblant les cellules cancéreuses. Leur pipeline comprend CLD-101, actuellement en essais de Phase 1/1b avec une étude de Phase 1b/2 à venir, et CLD-201 qui vise à commencer la Phase 1 en 2025. L'entreprise estime son marché adressable aux États-Unis entre 13 et 15 milliards de dollars.
Calidi Biotherapeutics (NYSE:CLDI) wird am 1. März 2025 um 19:00 Uhr ET in der Sendung RedChip Small Stocks, Big Money™ auf Bloomberg TV vorgestellt. Während des Interviews spricht CFO Andrew Jackson über die onkologische Virotherapie (OV)-Plattformen des Unternehmens zur Behandlung von Krebs.
Die Technologie des Unternehmens nutzt Stammzellen, um onkolytische Viren zu schützen, zu verstärken und zu verbessern, um Krebszellen anzuvisieren. Ihr Pipeline umfasst CLD-101, das sich derzeit in Phase 1/1b-Studien befindet, mit einer bevorstehenden Phase 1b/2-Studie, sowie CLD-201, das für den Beginn der Phase 1 im Jahr 2025 vorgesehen ist. Das Unternehmen schätzt seinen adressierbaren Markt in den USA auf 13 bis 15 Milliarden Dollar.
- Early clinical signals show efficacy and safety
- Pipeline includes two candidates in development
- Large addressable market of $13-15B in US
- Both drug candidates still in early clinical phases
- No approved products or revenue generation yet
ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
CLDI: https://www.redchip.com/assets/access/cldi_access.html
OSTX: https://www.redchip.com/assets/access/ostx_access.html
In an exclusive interview, Andrew Jackson, CFO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's innovative approach to transforming cancer treatment through its proprietary oncolytic virotherapy (OV) platforms. Jackson highlights Calidi's novel stem cell-based technology, designed to protect, amplify, and potentiate oncolytic viruses, enabling a more effective and targeted attack on cancer cells. He provides insights into Calidi's robust clinical pipeline, including CLD-101, currently in a Phase 1/1b trial with an upcoming Phase 1b/2 study, and CLD-201, targeting Phase 1 initiation in 2025. Additionally, Jackson outlines the company's significant market opportunity, with an addressable U.S. market estimated at
Paul Romness, CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's innovative approach to treating osteosarcoma (OS) and other solid tumors. Romness highlights OS Therapies' lead candidate, OST-HER2, a groundbreaking immunotherapy leveraging a bioengineered Listeria monocytogenes strain to trigger a targeted immune response against HER2-positive cancers. With statistically significant improvements in 12-month event-free survival for recurrent, fully resected metastatic OS, OST-HER2 is positioned for accelerated FDA approval, benefiting from Rare Pediatric Disease, Orphan Drug, and Fast Track designations. Romness also details OS Therapies' next-generation Tunable Antibody Drug Conjugate (tADC) platform, which utilizes proprietary SiLinker™ technology to deliver precision-targeted cancer treatments. With large market opportunities in osteosarcoma and HER2-positive solid tumors, and a strong leadership team driving regulatory and commercialization strategies, OS Therapies is well-positioned to advance novel oncology treatments and create significant value for investors.
CLDI and OSTX are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received rare pediatric disease, fast-track and orphan drug designations from the USFDA. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, with positive results released in the first quarter of 2025. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on ACCESS Newswire
FAQ
What is the current stage of Calidi Biotherapeutics' (CLDI) CLD-101 drug development?
What is the estimated market size for Calidi Biotherapeutics' (CLDI) cancer treatments?
When will Calidi Biotherapeutics (CLDI) begin Phase 1 trials for CLD-201?
When is Calidi Biotherapeutics' (CLDI) interview airing on Bloomberg TV?
